

REPORT ID AF-2026-326512	VERIFICATION CODE K2Z2-BFQY	CLIENT China Peptide Source	STATUS ACTIVE
PRODUCT Cartalax 25 mg	BATCH / LOT CART-96N9	SAMPLE RECEIVED Jul 28, 2026	ANALYSIS DATE Jul 30, 2026


CORE ANALYTICAL PANEL

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Cartalax - Purity	RP-HPLC	99.70%	≥99.00%	Conforms
Cartalax - Mass Identity	LC-MS	333.29 Da	333.29 ± 2 Da	Conforms
Net Content Quantity	Gravimetric	25.065 mg	25 mg Target	Measured

BIOSAFETY & SCREENING

SAFETY TEST	METHOD	OBSERVED LEVEL	LIMIT	STATUS
Endotoxin Assay (LAL)	LAL	0.33 EU/mg	≤ 5.0 EU/mg	Pass
Heavy Metal Screen (ICP-MS)	ICP-MS	0.027 ppm	< 0.1 ppm	Pass

RP-HPLC CHROMATOGRAM



Column: C18 Reverse-Phase (4.6 × 150 mm, 3.5 μm)

Flow Rate: 1.0 mL/min

Wavelength: 214 nm

VERIFICATION

K2Z2-BFQY

<https://analyticalformulations.com/verify/K2Z2-BFQY>

Lab ID: AFL-001 · FormuVerify™



Scan to verify certificate